Efficacy of anti-insulin-like growth factor i receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell

International Journal of Cancer

Volumn 131, Issue 9, 2012, Pages 2143-2152

  Kalra, Neetu ^a   Zhang, Jingli ^a   Yu, Yunkai ^a   Ho, Mitchell ^a   Merino, Maria ^a   Cao, Liang ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ADCC; cixutumumab; IGF IR; malignant mesothelioma; pleural mesothelioma

Indexed keywords

CELL SURFACE RECEPTOR; CIXUTUMUMAB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SODIUM CHLORIDE; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL LYSATE; CELL STRAIN; CELL STRAIN H2052; CELL STRAIN H226; CELL STRAIN H28; CONTROLLED STUDY; CORRELATION FUNCTION; DOWNSTREAM PROCESSING; DRUG BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MESOTHELIOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESOTHELIOMA; MICE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865544289     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27471     Document Type: Article

References (25)

1. Robinson BW, Lake RA,. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603. (Pubitemid 41434638)
2. Kaufman AJ, Flores RM,. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2011; 12: 201-16.
3. Vogelzang N, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P,. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44. (Pubitemid 46606305)
4. Pollak M,. Insulin and insulin-like growth factor signalling in neoplasia. Nat Res Cancer 2008; 8: 915-28.
5. Zha J, Lackner MR,. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010; 16: 2512-7.
6. Lee TC, Zhang Y, Aston C, Hintz R, Jagirdar J, Perle MA, Burt M, Rom WN,. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 1993; 53: 2858-64. (Pubitemid 23180528)
7. Hoang CD, Zhang X, Scott PD, Guillaume TJ, Maddaus MA, Yee D, Kratzke RA,. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 2004; 64: 7479-85. (Pubitemid 39372091)
8. Pass HI, Mew DJ, Carbone M, Matthews WA, Donington JS, Baserga R, Walker CL, Resnicoff M, Steinberg SM,. Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-1 receptor. Cancer Res 1996; 56: 4044-8. (Pubitemid 26284758)
9. Whitson BA, Jacobson BA, Frizelle S, Patel MR, Yee D, Maddaus MA, Kratzke RA,. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. Ann Thorac Surg 2006; 82: 996-1001.
10. Kai K, D'Costa S, Sills RC, Kim Y,. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009; 278: 49-55.
11. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R,. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7: 2575-88.
12. Gualberto A, Pollak M,. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009; 28: 3009-21.
13. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL,. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13 (18 Suppl): 5549s-55s. (Pubitemid 47510386)
14. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63: 8912-21. (Pubitemid 38064071)
15. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X,. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008; 68: 8039-48.
16. Feng M, Zhang J, Anver M, Hassan R, Ho M,. In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer 2011; 2: 123-31.
17. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladanyi M, Pao W,. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009; 4: e7273.
18. Rubini M, Hongo A, D'Ambrosio C, Baserga R,. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res 1997; 230: 284-92. (Pubitemid 27190648)
19. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K,. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 1275-80. (Pubitemid 46993549)
20. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G Jr, Johnson FM, Green S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009; 27: 2516-22.
21. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN,. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2011; 104: 68-74.
22. Basu B, Olmos D, de Bono JS,. Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer 2011; 104: 1-3.
23. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010; 28: 4240-6.
24. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetz SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumbab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion color study. Lancet Oncol 2010; 11: 129-35.
25. Olmos D, Tan DS, Jones R, Judson IR,. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 2010; 16: 183-94.